Mirum Pharmaceuticals Reports Q3 Operating Income

Mirum Pharmaceuticals reported third-quarter 2026 product sales of $185.72M, up 39.6% from the prior-year quarter. The company recorded a net loss of $40.77M, compared with net income of $2.91M, and diluted EPS was ($0.87), versus $0.05 a year earlier.Financial Highlights¹ Reported as “Product sale…